Bayer buys rights to market Levitra abroad

Share this article:
Bayer Healthcare has bought exclusive marketing rights to Levitra outside the U.S. from GlaxoSmithKline for 208 million euros, or around $270 million. Under the deal, GSK will also cut research and development spending on the drug by up to 15 million euros, or about $20 million.
Bayer originally co-marketed the number three ED drug worldwide with GlaxoSmithKline, but handed over U.S. marketing rights to its primary care products, including Levitra, to Schering-Plough in September. The German firm is refocusing its efforts on the European market while limiting promotion to high-profit specialty products in the U.S.
Bayer will now market Levitra exclusively in Asia, Latin America and Europe, where it has strong primary care sales forces, but will continue to co-promote the drug with GlaxoSmithKline in Italy.
As in the U.S., Levitra has lagged Lilly/Icos' Cialis in Europe, where the drug, known in France as "le weekender," boasts nearly twice the sales of its Bayer/GSK rival. In the U.S., IMS Health data pegged Levitra at 10 percent by October sales to Cialis' 18.7 percent and Viagra's 68.9 percent.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.